EP0472598A1 — Dry powder inhalation device.
Assigned to AstraZeneca AB · Expires 1992-03-04 · 34y expired
What this patent protects
A dry powder inhalation device comprising a housing (1) which defines a chamber (3) in communication with a port (4) for contact with the patient in the form of a mouthpiece or a nasal adapter (5) and an elongated support (8) of a powdered medicament. The device is designed so th…
USPTO Abstract
A dry powder inhalation device comprising a housing (1) which defines a chamber (3) in communication with a port (4) for contact with the patient in the form of a mouthpiece or a nasal adapter (5) and an elongated support (8) of a powdered medicament. The device is designed so that zones of predetermined dimensions of the elongated support (8) can be successively exposed inside the chamber (3). The device comprises one or more air intake orifices (2), so that when a patient inhales through his contact orifice (4), a current of air is established between the orifice (s) air intake (2) and the orifice for contact (4) with the patient, through the chamber (3), entraining in the air stream particles of breathable dimensions of the powdered medicament contained in the exposed area of the elongated support (8). The elongate support suitably comprises a strip, the surface of which releasably carries a micro-disintegrated medicament. The tape can be mounted in a removable cassette like a magnetic tape cassette.
Drugs covered by this patent
- Cutivate (FLUTICASONE PROPIONATE) · Teva Pharm
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.